A randomised trial presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) showed that switching from medications thought to cause weight gain did not lead to significantly greater weight reduction compared to staying on existing treatment, even when one of the replacement drugs has been shown to suppress weight gain. The study was designed to investigate the effects of swapping drugs associated with weight gain for ones that have not been associated with weight gain.
The integrase inhibitors dolutegravir and bictegravir have been associated with weight gain, as has tenofovir alafenamide (TAF).
Other studies have shown that people taking tenofovir disoproxil (TDF) gain less weight after starting treatment, suggesting that TDF may suppress weight gain in people who have started antiretroviral therapy (ART), whether the weight gain is associated with ART or has other causes.
Dr John Koethe of Vanderbilt University reported results from the DO-IT trial. The study recruited 145 people with obesity who were virally suppressed on a combination containing an integrase inhibitor and TAF.
Read the full news story at aidsmap.
All aidsmap reports from IAS 2025 can be accessed here.
SEE ALSO:
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.